Podcasts about Medical research

In this episode, we explore new treatments for hypertension, hereditary amyloidosis, and malaria prevention, along with insights on mosquito-borne disease control. We review idiopathic intracranial hypertension, follow a striking case of a hidden foreign body, and hear perspectives on worker safety, immigrant health care, the role of pharmaceutical wholesalers, and the arc of a medical career.

Ladies, it's Breast Cancer Awareness Month, so go get your boobies checked! We're also talking family lineage, growing up on a farm, and the groundbreaking treatment for Huntington's disease.00:00:00 - Introduction & Getting Started 00:02:04 - Fall Season & Halloween Decorations Debate 00:05:27 - Big Tea & Do Dog (Parent Nicknames) 00:15:27 - Big Family Reflections 00:20:08 - Family Genealogy & Lineage00:24:11 - Pop Culture & Science Discussion00:30:16 - Gene Therapy & Medical Research 00:33:07 - Eric Dane & ALS Awareness 00:37:11 - mRNA Vaccine Technology 00:38:36 - Wrapping Up & Superpower TalkMORE PODCAST EPISODES: https://youtube.com/playlist?list=PLTGuNbPgq2EartAwwgs_H-LVho3FvWnXpJUST LISTEN TO THE PODCAST: https://link.chtbl.com/imomsohardSEE US ON TOUR: (FALL DATES COMING SOON)https://www.imomsohard.com/WATCH OUR AMAZON PRIME SPECIAL: https://www.amazon.com/IMomSoHard-Live/dp/B07VBJ34DTIf you are interested in advertising on this podcast email ussales@acast.comTo request #IMOMSOHARD to be on your Podcast, Radio Show, or TV Show, reach out to talent@pionairepodcasting.comFOLLOW US: Facebook: https://www.facebook.com/imomsohardInstagram: https://www.instagram.com/imomsohard/Twitter: https://twitter.com/imomsohardGet our sponsor DISCOUNT CODES here!https://linktr.ee/imshpodcastABOUT US Female comedy duo Kristin Hensley and Jen Smedley have been performing, teaching, and writing comedy internationally for a combined 40+ years. They have been moms for one quarter of that time and it shows. How do they cope? They laugh about all of the craziness that comes with being a mom and they want you to laugh about it too! From snot to stretchmarks to sleepless nights, Kristin and Jen know firsthand that parenting is a hard job and they invite you to join them in taking it all a little less seriously (even if for a few short minutes a day). After all, Jen currently has four days of dry shampoo in her hair and Kristin's keys are still in her front door. They try, they fail, they support each other, and they mom as hard as they can.Disclaimer: This podcast is for entertainment purposes only. Views expressed on this podcast solely reflect those of the host and do not reflect the views of Pionaire. Hosted on Acast. See acast.com/privacy for more information.

The Guardian journalist Josh Halliday talks about Huntington's disease, the impact the rare inherited condition has had on his family and the hope there may now be a treatment. Help support our independent journalism at theguardian.com/infocus

In this expert interview, I sit down with Dr. Kevin Tracey—pioneer of the “inflammatory reflex” and a leading voice on neuroimmune science—to unpack how your nervous system can dial inflammation up or down. We explore what's really driving inflammatory arthritis, why the vagus nerve is a key switch for immune balance, and how neuromodulation (yes, stimulating nerves!) is opening new, drug-sparing frontiers for pain and flare control. You'll learn the difference between protective vs. destructive inflammation, practical ways to support vagal tone, and what the latest research means for people living with autoimmune and inflammatory conditions. If you've wondered how the brain, immune system, and joints talk to each other, this conversation connects the dots—and offers hope. Kevin J. Tracey, MD, is president and CEO of the Feinstein Institutes for Medical Research at Northwell Health, a pioneer of vagus nerve research and author of The Great Nerve. A leader in the scientific fields of inflammation and neuroscience, his lab studies vagus nerve stimulation and bioelectronic medicine. His contributions include first identifying the therapeutic action of monoclonal anti-TNF antibodies and discovering the specific reflex control of immunity by the nervous system, called the “inflammatory reflex.” These discoveries launched the new scientific field called bioelectronic medicine, which investigates the therapeutic applications of vagus nerve stimulation to cure disease. Dr. Tracey, a neurosurgeon, pursued studies of inflammation after the mysterious death of a toddler from sepsis who was in his care. His lab has since revealed molecular mechanisms of inflammation and identified the use of vagus nerve stimulation to treat it. An inventor on more than 120 U.S. patents and the author of more than 450 scientific publications, he is among the most highly cited scientists in the world. He co-founded the Global Sepsis Alliance, is the author of Fatal Sequence (Dana Press) and is a national and international lecturer. Check out Dr. Tracey's Ted Talk here:https://www.youtube.com/watch?v=AJH9KsMKi5M Free consultation with me and check out my memership with essential oils program: http://essentialwellnesscircle.com Follow me on instagram: https://instagram.com/annalaurabrownwellness Youtube channel with videos of this podcast and more: https://youtube.com/c/annalaurabrownhealthcoach    

Scientists are warning that academic publishing needs urgent reform in order to retain trust in the research system. Ian Sample tells Madeleine Finlay what has gone so wrong, and Dr Mark Hanson of the University of Exeter proposes some potential solutions. Help support our independent journalism at theguardian.com/sciencepod

Due to President Trump's sweeping federal cuts to medical research, many colleges and universities are faced with financial uncertainty. Why does the government want to make cuts to medical/science research? How worried are you about delays in potentially lifesaving research? UMass Chan Medical School Chancellor Dr. Michael F. Collins joined us on NightSide to discuss.

In this week's episode we'll learn about targeting the tissue factor pathway inhibitor with a monoclonal antibody to rebalance HEMOSTASIS in hemophilia A and B. In the phase 3 BASIS trial, the monoclonal antibody marstacimab reduced bleeding events, and was generally well tolerated, with no unanticipated side effects. After that: matched-donor allogeneic CD19 CAR-T for adult B-ALL. Given after allogeneic transplantation, CAR-donor lymphocyte infusion after lymphodepleting chemotherapy was associated with favorable efficacy and a tolerable safety profile. Finally: a new prognostic index for mycosis fungoides and Sézary syndrome. Comprised of four prognostic factors, the “CLIPI” could enable more personalized treatment of cutaneous lymphomas, identifying patients who may benefit from intensified treatment.Featured ArticlesMarstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trialMatched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletionA new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification

In this How I Treat podcast episode, Laura Michaelis, MD interviews Sung-Yun Pai, MD about their recently published article in Blood journal "How I treat Wiskott-Alrich syndrome". They highlight recent updates in treatment, including new risk-benefit calculations due to safer treatments and longer follow-ups. Challenges include late diagnosis, lack of well-matched donors, and limited gene therapy availability. They emphasize the importance of early referral to specialized centers and the need for discussions about curative intent therapies, including transplant and gene therapy. The conversation also covers the complexities of gene therapy, such as the need for better conditioning agents and the challenges of achieving full correction in all cell types.

Featuring articles on severe acute malnutrition with gastroenteritis in children, medical imaging and pediatric cancer risk, moderate hypertriglyceridemia, preventing RSV disease in healthy infants, and treating hypertension in rural South Africa; a review article on monoclonal gammopathy of undetermined significance; a Clinical Problem-Solving on a shifting frame; and Perspectives on insight into corporate governance, on pharmaceutical tariffs, and on OUD medications.

On this episode of JHLT: The Podcast, the Digital Media Editors invite author Dr. Ayumi Goda, from the Kyorin University Hospital in Tokyo, Japan, to discuss her team's paper, “Prevalence of occult HFpEF and age-specific efficacy of passive leg raise in pulmonary hypertension.” The discussion explores: How clinical observations led to the idea for a study on whether the passive leg raise could unmask occult HFpEF The potential diagnostic value of the passive leg raise in differing patient populations Age-specific cutoffs that may influence what kind of testing to use in clinical practice For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Subscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsWhat if the birth control you're taking every day is quietly changing your brain, your mood, your relationships—and even who you're attracted to? In this groundbreaking episode of hol+, Dr. Taz MD sits down with award-winning researcher and author Dr. Sarah Hill (This Is Your Brain on Birth Control) to reveal the shocking, little-known science of how hormonal contraception shapes not just your reproductive system, but your entire mind and body.From altered stress responses to shifts in attraction, depression risk in teens, and the controversial “bikini science” problem in medical research, Dr. Hill pulls back the curtain on decades of overlooked studies that every woman and parent should know about. She shares her own journey from evolutionary psychologist to outspoken women's health advocate, explaining why synthetic progestins are not the same as progesterone, how birth control affects your immune system, and why teenagers may be especially vulnerable to its mental health effects.If you're a woman in your teens, 20s, 30s, or 40s—or a parent guiding your daughter—this episode could change the way you think about hormone health, fertility, and your body's natural rhythms.Dr. Hill and Dr. Taz discuss:How birth control changes the brain's structure and functionThe difference between progesterone and synthetic progestins (and why it matters)Why “bikini science” has failed women in medical researchThe surprising link between birth control and partner attractionThe immune system's hidden connection to hormonal cyclingTeen mental health risks: depression, anxiety, and brain developmentSafer contraceptive choices and how to support your body if you use the pillHow nutrition and micronized progesterone might help offset side effectsThis conversation is more than just information — it's a wake-up call for how we study, prescribe, and support women's health.Topics Covered:Hormonal birth control's impact on the brainSynthetic hormones vs. bioidentical hormonesPartner choice and relationship satisfaction researchAutoimmunity and immune system differences in womenMental health risks for adolescent usersNon-hormonal birth control optionsNutritional and hormonal support strategiesConnect further to Hol+ at https://holplus.co/- Don't forget to like, subscribe, and hit the notification bell to stay updated on future episodes of hol+.About Dr. Sarah E. HillSarah E. Hill, Ph.D., is the author of This is Your Brain on Birth Control and an award-winning researcher who has spent most of her 20+ year career studying women, relationships, and health. In addition to having established an award-winning health and relationships lab at TCU, she has published nearly 100 academic research articles, is a sought-after public speaker, and sits on the scientific advisory boards for women's health companies such as Flo and 28 Wellness. Her research is regularly covered by national media, such as The Washington Post, The New York Times, and many others, and is regularly published in highly prestigious journals, including Journal of Personality and Social Psychology, Psychoneuroendocrinology, Psychological Science, and Health Psychology.Stay ConnectedSubscribe to the audio podcast: https://holplus.transistor.fm/subscribeSubscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsFollow Dr. Taz on Instagram: https://www.instagram.com/drtazmd/https://www.instagram.com/liveholplus/Join the conversation on X: https://x.com/@drtazmdTikTok: https://www.tiktok.com/@drtazmdFacebook: https://www.facebook.com/drtazmd/Connect with Dr. Sarah E. Hill:https://www.sarahehill.com/https://www.instagram.com/sarahehillphdHost & Production TeamHost: Dr. Taz; Produced by Rainbow Creative (Executive Producer: Matthew Jones; Lead Producer: Lauren Feighan; Editors: Jeremiah Schultz and Patrick Edwards)Don't forget to like, subscribe, and hit the notification bell to stay updated on future episodes of hol+Chapters00:00 Introduction06:12 The Flaws in Medical Research on Women17:51 Dr. Hill's Personal Journey with Birth Control21:43 The Science Behind Birth Control's Effects on the Brain27:45 How Birth Control Influences Attraction and Relationships34:44 Impact of Birth Control on Relationship Satisfaction37:31 Divorce Rates and Birth Control40:12 Hormones and Brain Influence41:35 Hormone Replacement Therapy (HRT): Progesterone vs. Progestin47:57 Birth Control and Mental Health in Teens01:00:16 Conclusion and Final Thoughts

Dr. Hoffman continues his conversation with Nicole Bell, the CEO of Galaxy Diagnostics and author of “What Lurks in the Woods.” 

This episode of the Intelligent Medicine podcast is a deep dive into the complexities of Lyme disease and other tick-borne illnesses. Nicole Bell, the CEO of Galaxy Diagnostics and author of “What Lurks in the Woods,” details the challenges of diagnosing tick-borne diseases, the limitations of current diagnostic tests, and the controversy around treatment methodologies. Nicole shares her personal journey that led her to this field after her husband was misdiagnosed with early-onset Alzheimer's, which was later revealed to be caused by advanced Lyme disease. They also discuss new diagnostic techniques, the importance of personalized treatment plans, and ongoing advocacy efforts to improve awareness and research funding for Lyme disease.

When the US president stood up at the podium and announced a link between autism and paracetamol, he sent alarm through the medical community and the public. Guardian science correspondent Hannah Devlin speaks to Reged Ahmad about what the science actually says about the painkiller and why experts fear Donald Trump is deliberately fostering a narrative of distrust

The US health secretary, Robert F Kennedy Jr, has long been consumed by the neurological condition autism – what causes it, and whether there's a treatment. This week, Donald Trump took on the cause, making claims about acetaminophen, also known as Tylenol and paracetamol, that were dismissed outright by medical experts around the world. Jonathan Freedland speaks to Carter Sherman, the reproductive health and justice reporter at Guardian US, about when and why the obsession with autism became political

In this week's episode, we'll learn more about relationships between Epstein-Barr virus genomic variants and human diseases, including hematological malignancies; the presence and timing of somatic GATA1 mutations and their relationship to a Down syndrome-specific form of leukemia; and new definitions for high-risk multiple myeloma that emphasize the presence of two or more high-risk cytogenetic abnormalities.Featured Articles:Association of Epstein-Barr virus genomic alterations with human pathologiesClinical significance of preleukemic somatic GATA1 mutations in children with Down syndromeBiallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Featuring articles on heart failure, provoked venous thromboembolism, chronic lymphocytic leukemia, and acute ischemic stroke; a review article on medical education to improve diagnostic equity; a case report of a man with embolic stroke and left ventricular apical aneurysm; two articles on the 2025 Lasker–DeBakey Clinical Medical Research Award; and Perspectives on structural and scientific racism, on the Gates Foundation's final chapter, and on Dr. Kolhouse and the cowboy.

Prostate cancer deaths have been climbing over the last decade in part due to confusion over who should be screened and treated. In part 1 of a three-part series on prostate cancer, host Sandra Lindsay speaks with Samir Taneja, MD, a trailblazer in urologic cancer innovation, to explore how modern diagnostics and treatments, such as the groundbreaking use of MRI technology, are transforming patient outcomes. As Northwell's senior vice president and system chair of urology, Dr. Taneja provides invaluable insights into the shifting landscape of prostate cancer care and the critical importance of early detection. Tune in to understand the vital steps needed to increase awareness and save lives. About Northwell Health Northwell Health is New York State's largest healthcare provider and private employer, with 21 hospitals, 850 outpatient facilities and more than 16,600 affiliated physicians. We're making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Get the latest news and insights from our experts in the Northwell Newsroom: Press releases Insights Podcasts Publications Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities. Get more expert insights from leading experts in the field — Northwell Newsroom.  Watch episodes of 20-Minute Health Talk on YouTube.  For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Interested in a career at Northwell Health? Visit the health system's job portal and explore our many opportunities.    

A trial is under way to find out if a £100 blood test could transform the way that the NHS diagnoses Alzheimer's disease. Alzheimer's is the leading cause of dementia and diagnosis is currently costly and time-consuming. To find out how this blood test could benefit patients, Ian Sample talks to Prof Jonathan Schott, who is co-leading the trial. He explains what the test involves and why it could pave the way for exciting new treatments for the devastating disease. Help support our independent journalism at theguardian.com/sciencepod

In this week's episode we'll learn about Azacitidine in VEXAS syndrome. Treatment can provide responses in patients with this complex autoinflammatory disorder. But relapse rates were high, so long-term therapy may be required to maintain disease control. After that: A step forward in precision blood matching. High-throughput array genotyping enables extended matching to reduce antibody formation. The results show the potential for reducing harm in regularly transfused patients. Finally, identifying a new vulnerability in TP53-mutated AML. Loss of the tumor suppressor BAP1 defines a unique subtype of TP53-mutated de novo AML. BAP1 loss also confers sensitivity to BCL-xL inhibitors in vivo, opening a new therapeutic avenue.Featured ArticlesEfficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEXArray genotyping of transfusion-relevant blood cell antigens in 6946 ancestrally diverse study participantsLoss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors

In this Review Series episode, Associate Editor Dr. Hervé Dombret speaks with Dr. Mark Litzow about the latest immunotherapy advances for Acute Lymphoblastic Leukemia (ALL). The discussion highlights innovative treatments like blinatumomab and inotuzumab, which are showing remarkable success in clinical trials, including an 85% three-year survival rate and over 90% complete remission in elderly patients. Researchers are focusing on reducing chemotherapy intensity, developing personalized treatment approaches, and identifying optimal immunotherapy strategies for different ALL subtypes. The conversation underscores a promising shift towards more targeted, less toxic treatments that could significantly improve patient outcomes across various age groups and disease characteristics. These emerging therapies represent a potential paradigm shift in ALL treatment, offering hope for more effective and less aggressive therapeutic interventions.Read Dr. Litzow's paper “Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia” or find the whole review series on acute lymphoblastic leukemia in volume 145 issue 14 of Blood Journal. 

Featuring articles on PI3K-altered colorectal cancer, type 2 diabetes, oral semaglutide, and proportional-assist ventilation; a review article on tumor lysis syndrome; a case report of a girl with chest pain and bone and liver lesions; and Perspectives on integrating pharmacotherapy into tobacco control, on Medicaid enrollees with chronic conditions, and on ultraprocessed food.

“Someday, devices that stimulate the vagus nerve may replace many of the drugs people take for chronic disease.”— Dr. Kevin Tracey  Key Resources & Links  Dr. Kevin J. Tracey's new book: The Great Nerve  Dr. Kevin J. Tracey's TedTalk: Watch Here  Center for Bioelectronic Medicine: Official Site  SetPoint Medical: Official Site  Clinical Trials: clinicaltrials.gov  Follow me on Instagram for updates and giveaways: @BarbaraHannahGrufferman  Why Listen to This Episode?  In this first of a two-part series, I sit down with Dr. Kevin J. Tracey, neurosurgeon, CEO of the Feinstein Institutes for Medical Research, and founder of the field of bioelectronic medicine. He's also one of the most widely cited medical experts in the world. Together, we explore the science behind the vagus nerve, a vast communication highway between your brain and body that is proving to be a powerful regulator of inflammation.  Just weeks ago, the FDA approved the first implantable vagus nerve device for rheumatoid arthritis, a breakthrough that could pave the way for treating other conditions without drugs. Dr. Tracey explains what this milestone means, how the device works, and why it could someday replace some of the medications people rely on for chronic disease management.  What You'll Learn in Part 1  What the vagus nerve is, where it's located, and why it matters.  How inflammation drives diseases like heart disease, Alzheimer's, arthritis, and more.  The story behind the FDA-approved device that may change how we treat rheumatoid arthritis.  Why bioelectronic medicine could represent a seismic shift in healthcare.  ENTER TO WIN A COPY OF ‘THE GREAT NERVE'! How to enter: listen to the episode, share the link on Instagram and tag me @BarbaraHannahGrufferman⁠ . You'll be automatically entered to win a copy of this seminal book.   If you're enjoying Age Better, I'd be so grateful if you left a quick review wherever you listen.      And if there's a topic or question you'd love for me to cover in a future episode, send a note to agebetterpodcast@gmail.com -- I love hearing from you!    Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textIn this week's Journal Club, Ben and Daphna review several recent neonatal studies with direct implications for practice.They begin with the BORN trial from Italy, which investigated whether transfusing preterm infants with cord blood–derived red blood cells, rather than adult donor blood, could reduce severe retinopathy of prematurity (ROP). While the intention-to-treat analysis showed no difference, per-protocol findings suggest potential benefits that warrant larger trials.Next, they review a large international cohort study of outcomes in infants born at 22–23 weeks, highlighting striking variability in survival and morbidity across networks, with Japan showing the highest survival rates.The EBNeo segment features Dr. Gabriel Altit discussing an Indian randomized trial comparing norepinephrine vs. dopamine as first-line therapy for neonatal septic shock. Although primary outcomes were similar, norepinephrine showed some favorable metabolic and perfusion markers.The hosts then cover a delivery room resuscitation study identifying expiratory tidal volumes of 4–5 ml/kg as key for successful lung aeration, a Canadian trial of atropine for neonatal intubation, and a retrospective study from Alabama on optimal timing and frequency of pulmonary hypertension screening in BPD.The episode concludes with a case report on the use of continuous glucose monitoring in a neonate with congenital hyperinsulinism.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

In this week's episode we'll learn about persistent changes in immune profiles in patients who have had diffuse large B-cell lymphoma, or DLBCL, and other cancers; that plasminogen activation and plasmin activity do not appear to play a role in routine physiological prevention of venous thromboembolism, or VTE; and about a novel mechanism that makes hematological malignancies carrying epigenetic mutations susceptible to PARP inhibitors.Featured Articles:Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatmentPlasminogen activation and plasmin activity are not required to prevent venous thrombosis/thromboembolismTransposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer

Featuring articles on hypertrophic cardiomyopathy, rehabilitation after myocardial infarction in older adults, the 2024 Marburg virus disease outbreak in Rwanda, and medications for opioid use disorder in county jails; a case report of a woman with dyspnea and fatigue; a Medicine and Society on the race-correction debates; and Perspectives on recent efforts toward equity, on medical research funding in a divided America, and on the end of days.

In this week's episode, we'll learn about how TET2 is often mutated in myeloid malignancies and clonal hematopoiesis. In new work, expansion of Tet2-mutant HSPCs was dependent on Ncoa4, the cargo receptor mediating ferritinophagy. We'll iron out the implications. After that: a double-oh-seven license to kill in T-cell leukemia/lymphoma. WU-CART-007 is an off-the-shelf CAR T product with manageable safety and encouraging efficacy. With further work, it could become a new option for patients in urgent need of therapy. Finally: a comprehensive genetic study of classical Hodgkin lymphoma using circulating tumor DNA. This new research provides novel and complex insights on genetic subtypes, prognostic biomarkers, neoantigens in the disease environment, and more.Featured Articles:An in vivo barcoded CRISPR-Cas9 screen identifies Ncoa4-mediated ferritinophagy as a dependence in Tet2-deficient hematopoiesisPhase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignanciesA comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA

Featuring articles on obesity, type 1 diabetes, syphilis, and heparin-induced thrombocytopenia; a review article on the management of acute type B aortic dissection; a Clinical Problem-Solving describing a fruitful workup; and Perspectives on the corporatization deal, on advancing physician-scientist training in China, and on the rise of drug innovation in China.

On this episode of JHLT: The Podcast, the Digital Media Editors invite first author Ahmet Bilgili, from the University of Florida's Congenital Heart Center, and senior author Eric I. Jeng, MD, from the University of Florida's MCS program. Bilgili and Dr. Jeng discuss their paper, “Optimal pretransplant duration with HeartMate III left ventricular assist device: A contemporary analysis.” The discussion explores: Prior gaps in the literature regarding contemporary HM3 outcomes in relation to transplantation—and the study's potential influence on policy Which length of HM3 support influenced better post-transplant outcomes—and which ages were most influenced How these findings might change standard practice For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.  

Kevin J. Tracey is president and CEO and the Karches Family Distinguished Chair in Medical Research at the Feinstein Institutes for Medical Research; professor of Molecular Medicine and Neurosurgery at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; and Executive Vice President, Research, at Northwell Health. A leader in the scientific fields of inflammation and bioelectronic medicine, his contributions include discovery and molecular mapping of neural circuits controlling immunity. Dr. Tracey received his BS in chemistry, summa cum laude, Phi Beta Kappa, from Boston College in 1979, and his MD from Boston University in 1983. He trained in neurosurgery from 1983 to 1992 at the New York Hospital-Cornell University Medical Center and was a guest investigator at the Rockefeller University before moving in 1992 to the Feinstein Institutes. There he directs the Laboratory of Biomedical Science and was appointed president and CEO in 2005.An inventor of more than 120 United States patents and author of more than 400 scientific publications, he cofounded the Global Sepsis Alliance, a non-profit organization supporting the efforts of more than 1 million sepsis caregivers in over 70 countries. Dr. Tracey is the author of Fatal Sequence (Dana Press) and delivers lectures nationally and internationally on inflammation, sepsis, the neuroscience of immunity, and bioelectronic medicine.

A physician dad shares how politics are disrupting research, parenting transgender kids, and the sports debate.In this episode, Diana sits down with her husband, Arthur, a physician researcher and parent, to talk about how today's shifting policies and headlines affect real families. Together, they cover three big themes:The ripple effects of political decisions on medical research and patient careWhat it means for parents of transgender kids to prepare and protect their familiesThe science, myths, and realities behind the transgender sports debateThis candid conversation sheds light on how systemic changes impact everyday lives, and what families and allies can keep in mind moving forward.If you're taking something away from our podcast, we'd appreciate it if you'd take a moment to provide us with a review; the more listeners and reviews, the more people we can reach and support. As always, feel free to reach out to us at transparentlyspeakingpodcast@gmail.com.

Blood Editor, Dr. Thomas Coates interviews Dr. Emanuele Angelucci on his paper, "How I manage iron overload in the hematopoietic cell transplantation setting" which is featured in Blood's "How I Treat Series on Iron Overload in Hematologic Disorders". See the full How I Treat series in volume 145 issue 4 of Blood. 

In this week's episode we'll learn about targeting NPM1 in acute myeloid leukemia. Researchers report the first clinical evidence of a menin inhibitor inducing complete remissions in AML with a NPM1 mutation. This validates NPM1 as a new therapeutic target in AML, alongside FLT3, IDH1/2, and KMT2A. Also on the podcast: targeting CD137 to prevent graft-versus-host disease. In nonhuman primates, a single dose of a CD137 antibody-drug conjugate provided long-term protection, with one important caveat: the potential for viral reactivation.Featured Articles: Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyA single dose of a CD137 antibody–drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD

Kevin J. Tracey, MD is president and CEO of the Feinstein Institutes for Medical Research at Northwell Health, a pioneer of vagus nerve research and author of the recent book, The Great Nerve: The New Science of the Vagus Nerve and How to Harness Its Healing Reflexes. This episode is brought to you by:Eight Sleep Pod Cover 5 sleeping solution for dynamic cooling and heating: EightSleep.com/Tim (use code TIM to get $350 off your very own Pod 5 Ultra.)AG1 all-in-one nutritional supplement: https://DrinkAG1.com/Tim (1-year supply of Vitamin D plus 5 free AG1 travel packs with your first subscription purchase.)Wealthfront high-yield cash account: https://Wealthfront.com/Tim (Start earning 4.00% APY on your short-term cash until you're ready to invest. And when new clients open an account today, you can get an extra fifty-dollar bonus with a deposit of five hundred dollars or more.) Terms apply. Tim Ferriss receives cash compensation from Wealthfront Brokerage, LLC for advertising and holds a non-controlling equity interest in the corporate parent of Wealthfront Brokerage. See full disclosures here.Timestamps:00:00 Tim's intro: why he dismissed vagus-nerve hype06:34 What the vagus nerve actually is, plus common myths11:31 Breaking news: FDA approval for SetPoint's RA implant + Kelly Owens's turnaround21:11 Inflammation 101: when healing turns harmful31:37 Bioelectronic medicine: from lab insight to real devices55:26 TNF, IL-1, and IL-6: immune drivers and what VNS modulates56:06 Exercise & recovery: vagal signals, IL-6, and adaptation56:30 Cold exposure & breathwork: sympathetic spike, parasympathetic payoff59:04 Chronic inflammation today: prevalence, diagnostics, and uncertainty59:53 Autoimmunity: genes, environment, infections01:01:08 Stress hormones, personality traits, and metabolic fallout01:05:41 VNS tech landscape: implants, focused ultrasound, and what's just TENS01:11:14 Ear maps, revisited: the real science behind auricular stimulation01:27:52 Ulf Andersson: auricular TENS, famotidine, and a depression turnaround01:36:48 Depression & inflammation: where VNS helps (and where it doesn't)01:41:38 Body-brain loop: how inflammation signals ride the vagus nerve01:42:56 Why VNS can lift mood: a working theory01:43:22 Ulf's setup: electrode placement and twice-daily routine01:44:37 Acupuncture, fertility, and plausible vagal links01:47:23 Chronic pain through an inflammation lens01:48:34 Neural “engrams”: how the brain can store inflammatory memories02:02:35 Cervical TENS vs. true VNS: mechanisms and open questions02:12:15 On stage with the Dalai Lama: blue energy and two vagus nerves02:16:55 Closing thoughts: self-care vs. medical devices, and what's next*For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsorsSign up for Tim's email newsletter (5-Bullet Friday) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Discover Tim's books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissYouTube: youtube.com/timferrissFacebook: facebook.com/timferriss LinkedIn: linkedin.com/in/timferrissPast guests on The Tim Ferriss Show include Jerry Seinfeld, Hugh Jackman, Dr. Jane Goodall, LeBron James, Kevin Hart, Doris Kearns Goodwin, Jamie Foxx, Matthew McConaughey, Esther Perel, Elizabeth Gilbert, Terry Crews, Sia, Yuval Noah Harari, Malcolm Gladwell, Madeleine Albright, Cheryl Strayed, Jim Collins, Mary Karr, Maria Popova, Sam Harris, Michael Phelps, Bob Iger, Edward Norton, Arnold Schwarzenegger, Neil Strauss, Ken Burns, Maria Sharapova, Marc Andreessen, Neil Gaiman, Neil de Grasse Tyson, Jocko Willink, Daniel Ek, Kelly Slater, Dr. Peter Attia, Seth Godin, Howard Marks, Dr. Brené Brown, Eric Schmidt, Michael Lewis, Joe Gebbia, Michael Pollan, Dr. Jordan Peterson, Vince Vaughn, Brian Koppelman, Ramit Sethi, Dax Shepard, Tony Robbins, Jim Dethmer, Dan Harris, Ray Dalio, Naval Ravikant, Vitalik Buterin, Elizabeth Lesser, Amanda Palmer, Katie Haun, Sir Richard Branson, Chuck Palahniuk, Arianna Huffington, Reid Hoffman, Bill Burr, Whitney Cummings, Rick Rubin, Dr. Vivek Murthy, Darren Aronofsky, Margaret Atwood, Mark Zuckerberg, Peter Thiel, Dr. Gabor Maté, Anne Lamott, Sarah Silverman, Dr. Andrew Huberman, and many more.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

First, The Indian Express' Diplomatic Affairs Editor Shubhajit Roy breaks down what the recent visit of Chinese Foreign Minister Wang Yi signals about evolving India–China ties, the friction and convergence in forums like BRICS and SCO.Next, we talk to The Indian Express' Anonna Dutt on how the Indian Council of Medical Research is expanding wastewater surveillance to track outbreaks of diseases and how this public health tool could provide early warning signals in 50 cities across India. (16:25)And finally, we turn to rural Haryana, where The Indian Express' Sukhbir Siwach explains a rare Supreme Court-supervised recount has reversed the outcome of a 2022 sarpanch election. (26:13)Hosted by Ichha SharmaProduced and written by Shashank Bhargava, Niharika Nanda and Ichha SharmaEdited and mixed by Suresh Pawar

Ontario Premier Doug Ford says he'll crack down on labs using cats and dogs in experiments after revelations that beagles were subjected to heart attack studies at St. Joseph's Health Care in London, Ontario. The case has ignited debate over the role of animals in science. We hear from animal bioethicist Andrew Fenton, Western University researcher Arthur Brown, and Executive Director of the Canadian Centre for Alternatives to Animal Methods, Charu Chandrasekera, who advocates for replacing animal testing with new technologies.

In this week's episode we'll learn about how by combining PET response with circulating tumor DNA, or  ctDNA, in newly treated patients with follicular lymphoma, investigators identify those patients likely to progress within 24 months of initial treatment, also known as POD24. After that: Immune hotspots in aplastic anemia. These newly identified hotspots potentially represent sites in the bone marrow where the active immune response takes place, driving the destruction of hematopoietic stem and progenitor cells. Finally, allogeneic transplantation for Hodgkin lymphoma in the checkpoint inhibitor era. In a large, retrospective study, patients with prior checkpoint inhibitor exposure had remarkable outcomes, particularly when post-transplant cyclophosphamide was used.Featured Articles: Combined PET and ctDNA response as predictors of POD24 for follicular lymphoma after first-line induction treatmentImaging Mass Cytometry Reveals the Order of Events in the Pathogenesis of Immune-Mediated Aplastic AnemiaOutcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis

This is our last show from Ireland for a while. We've had some very special houseguests, including our friends Alan and Lisa Robertson from Duck Dynasty and the Unashamed Podcast. They had a great time seeing the sights with us—watch the podcast to see our journey to a very interesting pub.Also on today's show, we reveal how the “nice people” in society are declaring YOU unfit for existence, from the womb to old age. We bring you a chilling interview exposing the questionable science and moral vacuum in the gold rush for designer babies.And watch the show to learn about the horrific expansions of Canada's assisted suicide law. You won't believe how common it has become and how much of America is heading down the same path.The New Yorker magazine—home of great writing and writers—has a racist on its staff. But don't worry—she's the fashionable kind. She only hates white people, so the left has no problem with that.We also have an exclusive story this week as we uncover the great veteran disability scam and how America's love affair with its military is allowing bad actors to rob us blind. Listen as the financial Jerry Springer exposes a veterans' scandal while trying to pound sense into some Gen Z deadbeats.Leave a comment wherever you get our content—you never know, we may read it on the show!Remember, we are a 501(c)(3) nonprofit. Please visit our website, unreportedstorysociety.com, and give what you can so we can keep bringing you our show and special projects. Your donation is tax-deductible.Click here to donate to the Unreported Story Society: ⁠https://unreportedstorysociety.com/⁠Did you know you don't have to wait a week to get the scoop? Subscribe to our Stories.io Substack for news and views every day.Click here to read Phelim's story on the abuse of VA disability benefits: https://phelimmcaleer.substack.com/p/exposing-the-great-veteran-disability?utm_campaign=email-half-post&r=58t52b&utm_source=substack&utm_medium=emailSubstack link: https://phelimmcaleer.substack.com/

Featuring articles on lung cancer, vasomotor symptoms in breast cancer, autoimmune pulmonary alveolar proteinosis, and high-risk cutaneous squamous-cell carcinoma; a review article on educational strategies for clinical supervision of AI use; a case report of a woman with fatigue and myalgias; a Sounding Board on vaccine policy in the U.S.; and Perspectives on preventive care at the Supreme Court, regulating private equity in health care, reforming the prescription drug user fee program, and on the consultant.

On this episode of JHLT: The Podcast, the Digital Media Editors invite first author Luke Williams, a cardiothoracic surgery trainee at Royal Papworth Hospital, NHS Blood and Transplant Clinical Research Fellow, and a PhD student at Cambridge University in the UK. Luke discusses his paper, “The United Kingdom's experience of controlled donation after circulatory death direct procurement of lungs with concomitant abdominal normothermic regional perfusion with an analysis of short-term outcomes.”   The discussion explores: Requirements, regulations, and practices in the UK around DCD procurement and A-NRP How survival rates differ and what they might imply about primary graft dysfunction in DCD versus DBD Further work planned in the area in the UK and throughout Europe For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.   Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.  

In this week's episode, we'll learn more about how exogenous CD19 stimulation affects CAR T-cell persistence in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy; new algorithms that incorporate sequential rapid immune-assays, intended to improve diagnosis of heparin-induced thrombocytopenia, and resource-adaptive survival prediction models to help guide management of patients with chronic myelomonocytic leukemia.Featured Articles:Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALLSequential combinations of rapid immunoassays for prompt recognition of heparin-induced thrombocytopeniaBLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

Daniel Blumenthal, VP of Strategy at MDClone, is building synthetic data models to mimic real patient data without the need to protect the identity of individuals. This type of data is being utilized in drug discovery and development, building predictive tools and new care models, and to better understand biases in clinical trials making them more representative. AI tools play an essential role in generating and validating synthetic data as well as integrating it into various processes and environments. Daniel explains, "Synthetic data means different things to different people. So I definitely would want to start with sharing what it usually means to MDClone, which is creating data based on real populations of patients, real patient data. Learning from that real patient data, extracting essentially the statistics from that data, understanding the relevant patterns that exist inside that data, and then, based on the statistics alone, generating a brand-new set of data, a brand-new set of people, and the synthetic data that we generate."   "If you look at it, essentially with your naked eye, you wouldn't know it's not real people. It has the same structure, has the same content appearance, and yet, inside, synthetic data contains no real people. So very different from other approaches to protecting patient privacy, which take a patient data set and hash data, mask data, or remove information like IDs, names, or locations."  "Instead of taking that sort of approach, synthetic data actually generates a brand-new set of people, fake people, that in our case, as we build it, maintain the same statistical properties, such that any analysis you want to complete, you could accomplish using the synthetic dataset just as you would with the original dataset. That it will yield the same meaningful conclusions as the synthetic that it would with the original." #MDClone #MedAI #AI #SyntheticData #DrugDevelopment #DrugDiscovery #ClinicalTrials #PatientPrivacy mdclone.com Download the transcript here

Daniel Blumenthal, VP of Strategy at MDClone, is building synthetic data models to mimic real patient data without the need to protect the identity of individuals. This type of data is being utilized in drug discovery and development, building predictive tools and new care models, and to better understand biases in clinical trials making them more representative. AI tools play an essential role in generating and validating synthetic data as well as integrating it into various processes and environments. Daniel explains, "Synthetic data means different things to different people. So I definitely would want to start with sharing what it usually means to MDClone, which is creating data based on real populations of patients, real patient data. Learning from that real patient data, extracting essentially the statistics from that data, understanding the relevant patterns that exist inside that data, and then, based on the statistics alone, generating a brand-new set of data, a brand-new set of people, and the synthetic data that we generate."   "If you look at it, essentially with your naked eye, you wouldn't know it's not real people. It has the same structure, has the same content appearance, and yet, inside, synthetic data contains no real people. So very different from other approaches to protecting patient privacy, which take a patient data set and hash data, mask data, or remove information like IDs, names, or locations."  "Instead of taking that sort of approach, synthetic data actually generates a brand-new set of people, fake people, that in our case, as we build it, maintain the same statistical properties, such that any analysis you want to complete, you could accomplish using the synthetic dataset just as you would with the original dataset. That it will yield the same meaningful conclusions as the synthetic that it would with the original." #MDClone #MedAI #AI #SyntheticData #DrugDevelopment #DrugDiscovery #ClinicalTrials #PatientPrivacy mdclone.com Listen to the podcast here

Featuring articles on overweight, obesity and diabetes; lactated Ringer's solution versus normal saline; and spinal muscular atrophy; a review article on metabolic dysfunction–associated steatotic liver disease; a case report of a woman with respiratory failure and abnormal chest imaging; and Perspectives on dismantling public health infrastructure, on progress lost, on private law in American health care, and on the serendipitous dance between life and death.

It's a mystery that has long puzzled researchers. Freud called the phenomenon infantile amnesia, and for many years scientists have wondered whether it's a result of failure to create memories or just a failure to retrieve them. In this episode from March 2025, Ian Sample speaks to Nick Turk-Browne, a professor of psychology at Yale University, whose research appears to point to an answer. Help support our independent journalism at theguardian.com/sciencepod

Featuring articles on treatments for chronic kidney disease and type 2 diabetes, bubonic plague, and advanced breast cancer; a review article on hypogonadism; a Clinical Problem-Solving describing gasping for strength; a Medicine and Society on the infant mortality rate; and Perspectives on profit-driven medicine, on lead contamination in Milwaukee schools, on training health communicators, and on ER and becoming a physician.

Sweet poison? New doubts cast over safety of erythritol; Is Greek yogurt a good way to enhance protein intake? Comparing whey, soy, and pea protein isolates; When taking supplements, is it advisable to take periodic breaks to enhance their effectiveness? Tommy John surgery pioneer and longtime Mets medical director dies at 68; Ivermectin, once branded useless “horse paste,” may prove a new weapon against malaria; New findings challenge notion that humans and apes share 99% of their DNA.

Henrietta Lacks was the first human being that we know of to get close enough to 'immortality' to touch it. She died more than 50 years ago but her cells live on.'HeLa' cells were the first human cells to be grown for research, and have been vital in medical advances since the 1950s.But what fascinated science major Rebecca Skloot the most about these cells, was how little was known about the woman behind the name.So she set out to discover who Henrietta Lacks really was.Further informationFirst broadcast in July, 2010.The Immortal Life of Henrietta Lacks is published by Picador.Rebecca's book was turned into a film starring Oprah Winfrey.You can learn more about Henrietta online.You can also hear Richard's full conversation with Helen Macdonald on the ABC Listen App or wherever you get your podcasts. You can also read all about the Conversations origin story on the ABC News website.This episode of Conversations explores science, science communication, weird science, female scientists, modern history, medicine, medical history, medical research, cells, cancer, curing disease.

Featuring articles on myeloma, mitochondrial DNA disease, cardiac surgery, and squamous-cell carcinoma; a review article on motor vehicle crash prevention; a case report of a woman with seizure-like activity and odd behaviors; a Medicine and Society article on the evaluation of occupational pulmonary impairment; and Perspectives on Covid-19 vaccines, on public policies, and on living on the edge of the valley of the sick.

In 2024, the Oxford English Dictionary announced its word of the year was ‘brain rot'. The term relates to the supposedly negative effects of consuming social media content, but it struck a chord more widely with many who feel they don't have the mental capacity they once had. Gloria Mark, a professor of informatics at the University of California, Irvine, has been studying our waning attention spans for 20 years. In this episode from January 2025, she tells Madeleine Finlay why she believes our powers of concentration are not beyond rescue, and reveals her top tips for finding focus. Help support our independent journalism at theguardian.com/sciencepod